

component and to at least one of (1) enhance the movement of the therapeutic component across a lipid membrane and (2) enhance the movement of the therapeutic component across a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic component and being selected from the group consisting of anionic polymers, fatty acids, derivatives thereof and mixtures thereof, the complex remaining substantially intact in an aqueous environment, each of enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

37. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is present in an amount effective to enhance the permeability of the therapeutic component relative to the permeability of the therapeutic component without the efficacy enhancing component.

A  
38. (New Claim) A composition of claim 36 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

39. (New Claim) A composition of claim 38 wherein the alpha-2-adrenergic component comprises a quinoxaline component.

Sub B2  
40. (New Claim) A composition of claim 39 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, and derivatives thereof and mixtures thereof.

41. (New Claim) A composition of claim 36 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals,

ST AVAILABLE C

amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, derivatives thereof and mixtures thereof.

42. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of fatty acids, derivatives thereof and mixtures thereof.

43. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of saturated fatty acids and unsaturated fatty acids, derivatives thereof and mixtures thereof.

A 44. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of a fatty acid with more than 12 carbon atoms per molecule, derivatives thereof and mixtures thereof.

45. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of a docosahexanoic acids, derivatives thereof and mixtures thereof.

46. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of a linolenic acid, derivatives thereof and mixtures thereof.

47. (New Claim) A composition of claim 36 wherein the efficacy enhancing component has a therapeutic effect.

BEST AVAILABLE COPY

*Sub B3*

48. (New Claim) A composition of claim 36 wherein the efficacy enhancing component in the complex has a therapeutic effect.

49. (New Claim) A composition of claim 36 wherein the efficacy enhancing component has a therapeutic effect without being in the complex with the therapeutic component.

50. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is effective to reduce intraocular pressure when the composition is administered to the eye.

*Sub B4*

51. (New Claim) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of prostanoids, derivatives thereof and mixtures thereof.

*A*

52. (New Claim) A composition of claim 36 wherein the therapeutic component comprises a 5-bromo-6-(2-imidazolylamino) quinoxaline,

the efficacy enhancing component is selected from the group consisting of docosahexanoic acids, linolenic acids, prostanoids, derivatives thereof and mixtures thereof; and

the efficacy enhancing component enhances the movement of the therapeutic component across a biological membrane under physiological conditions.

53. (New Claim) A composition of claim 36 wherein the complex is not present in a solution.

54. (New Claim) A composition of claim 36 wherein the complex is dissociable in a biological environment to provide a therapeutic effect.

**BEST AVAILABLE CO.**

55. (New Claim) A composition of claim 36 which includes at least one additional therapeutic component and the efficacy enhancing component is complexed with both the therapeutic component and the additional therapeutic component.

56. (New Claim) A composition of claim 36 wherein a single therapeutic component is present in the complex with more than one efficacy enhancing component.

57. (New Claim) A composition of claim 36 which is ophthalmically acceptable.

58. (New Claim) A composition of claim 36 which further comprises a carrier.

A1 *Per B5*  
59. (New Claim) A composition comprising:  
an adrenergic agonist; and  
a fatty acid selected from the group consisting of docosahexanoic acids, linolenic acids, derivatives thereof and mixtures thereof,  
wherein the adrenergic agonist is present in a complex with the fatty acid, the complex substantially remains intact in an aqueous environment.

60. (New Claim) A composition comprising a complex and a carrier component, the complex comprising:  
a therapeutic component, and  
an efficacy enhancing component,  
wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, derivatives thereof and mixtures thereof, and is present in an amount effective to at least one of (1) enhance the movement of the therapeutic component across a lipid membrane and (2) enhance the movement of the therapeutic component across a biological membrane under

AVAILABLE CC.

physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

61. (New Claim) A composition of claim 60 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

62. (New Claim) A composition of claim 61 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

*part B6*  
63. (New Claim) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, 5-bromo-6- (2-imidozolin-2-ylamino) quinoxaline, derivatives thereof and mixtures thereof.

*A*  
64. (New Claim) The composition of claim 60 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, derivatives thereof and mixtures thereof.

65. (New Claim) A composition of claim 60 which has a pH of about 7 or greater.

66. (New Claim) A composition of claim 60 which has a pH in a range of about 7 to about 9.

BEST AVAILABLE COPY